Maximum quantity allowed is 999
请选择数量
CAS RN: 17902-23-7 | 產品號碼: F0635
5-Fluoro-1-(tetrahydro-2-furfuryl)uracil
×
![]()
×
* 以上價格已含運費關稅等但一些需要海運以及乾冰運輸的產品除外,詳情請與
當地經銷商
洽詢。
* TCI會時常優化儲存條件,儲存溫度請以在線目錄為準，敬請留意。
產品規格
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(with Total Nitrogen) | min. 98.0 % |
| Melting point | 167.0 to 171.0 °C |
| NMR | confirm to structure |
性質
| 熔點 | 169 °C |
GHS
| 圖形表示 |
|
| 信號詞 | Danger |
| 危險性說明 | H300 : Fatal if swallowed. H373 : May cause damage to organs through prolonged or repeated exposure. |
| 防範說明 | P501 : Dispose of contents/ container to an approved waste disposal plant. P260 : Do not breathe dust/ fume/ gas/ mist/ vapors/ spray. P270 : Do not eat, drink or smoke when using this product. P264 : Wash skin thoroughly after handling. P314 : Get medical advice/ attention if you feel unwell. P301 + P310 + P330 : IF SWALLOWED: Immediately call a POISON CENTER/doctor. Rinse mouth. P405 : Store locked up. |
相關法規
| RTECS # | YR0450000 |
運輸資料
| UN編號 | UN2811 |
| 類別 | 6.1 |
| 包裝類別 | II |
| HS編碼* | 2940.00-000 |
Application
Tegafur: A Prodrug of an Active Antitumor 5-FU
Tegafur is a prodrug that is metabolized by cytochrome P 450 to an active antitumor 5-FU [F0151]. Tegafur is often used as combined agents such as UFT (tegafur and uracil [U0013] at a molar ratio of 1:4) or S-1 (tegafur, gimeracil [C2243] and potassium oxonate [O0164] at a molar ratio of 1:0.4:1) to increase the plasma and tumor 5-FU concentrations. Determination of the combined agents in plasma is important to evaluate the safety and efficacy of them. (The product is for research purpose only.)
References
- Effect of coadministration of uracil or cytosine on the antitumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents
- Bioactivation of Tegafur to 5-fluorouracil is catalyzed by cytochrome P 450 2A6 in human liver microsomes in vitro
- Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes
- Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators
- Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review
- Determination of S-1 (combined drug of tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate) and 5-fluorouracil in human plasma and urine using high-performance liquid chromatography and gas chromatography-negative ion chemical ionization mass spectrometry
- Determination of tegafur, 5-fluorouracil, gimeracil and oxonic acid in human plasma using liquid chromatography-tandem mass spectrometry
考研文獻
文檔
產品介紹報導
產品文件 （部分產品的分析圖譜無法提供，敬請諒解。）
SDS
請選擇語言。
請求的SDS不可用。
如需更多幫助，請聯繫我們 。
產品規格
檢驗報告(CoA)及其他文檔
請輸入批號
輸入的批號不正確
示例 CoA
可下載CoA示例。注：該示例可能非最新批次的CoA。
目前沒有該產品的 CoA 示例。
分析圖譜
請輸入批號
輸入的批號不正確
很抱歉，您搜索的分析圖譜無法提供。